Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Shawn Donahue who wrote (116)	11/17/2005 2:06:54 AM
From: EACarl	Respond to of 237

RE "MultiCell ImmunoTherapeutics, has elevated MCT-465 to lead drug candidate status and will commence evaluation of MCT-465 in preclinical animal models" Thanks for posting that Shawn. It makes the point at how desperate the poor management at MUCKLE is getting. Tossing out a PR relating to the current "hot" flu subject. Unfortunately, even that is getting the result of lower and lower highs for the pps. Their almost out of cash (AGAIN), and the share price is near 2 year lows making for another horrific dilution likely on the way. STILL NOTHING has entered phase I, and the only decent contract they had isn't even being paid the minimum payments to them! All in all a terrible stock. MUCKLE has been the "Murphy" of stocks - anything that could go wrong, did go wrong. The only thing sadder, is some of you guys not wanting to admit it. Hows that AMEX listing going? - NOT! How'd that REVERSE split do for you? - NOT! How'd all that wasted money of paid coverage help? - NOT.

To: Shawn Donahue who wrote (116)	11/23/2005 11:07:39 PM
From: Shawn Donahue	Respond to of 237

Form 8-K for MULTICELL TECHNOLOGIES, INC. 22-Nov-2005 Entry into Material Agreement Item 1.01. Entry into a Material Definitive Agreement. On November 16, 2005, the board of directors of MultiCell Technologies, Inc. (the "Company") approved resolutions to pay Stephen Chang, a member of the board of directors and the Company's President, $200,000 owed to Mr. Chang (the "Accrued Amount") by MultiCell Immunotherapeutics, Inc. ("Sub") that were accrued by Sub prior to the Company's acquisition of Sub on September 7, 2005. The Accrued Amount represents compensation in consideration of services of Mr. Chang to Sub prior to the acquisition. Following the acquisition, Mr. Chang has served as President of Sub. Mr. Chang has also previously entered into an Employment Agreement with the Company dated as of February 1, 2005. Mr. Chang will receive the Accrued Amount as follows: (a) $100,000 in November 2005, $50,000 of which is paid in cash and $50,000 of which is paid in shares of the Company's Common Stock based on the closing price per share of the Company's Common Stock on November 16, 2005 (the date of issuance), and (b) $100,000 in 2006, $50,000 of which is to be paid in cash and $50,000 of which is to be paid in shares of the Company's Common Stock based on the closing price per share of the Company's Common Stock on the date of issuance. Accordingly, the Company issued to Mr. Chang 73,529 shares of Common Stock on November 16, 2005 pursuant to the Company's 2000 Employee Benefit Plan in consideration of the $50,000 to be paid in shares in November 2005. The closing price per share of the Company's Common Stock on November 16, 2005 was $0.68. On November 16, 2005, the board of directors of the Company amended an outstanding option to purchase 50,000 shares of Common Stock originally granted on or about October 12, 2001 to Ronald Faris, the Company's Senior Vice President and Chief Science Officer, pursuant to the Company's 2000 Stock Option Plan. The option was amended to extend the termination date from October 11, 2005 to October 11, 2006. The closing price per share of the Company's Common Stock on October 11, 2005 was $0.60, the same price as the exercise price per share of the option being amended. All other terms of the option remain unchanged, including the exercise price per share. Mr. Faris has also previously entered into an Employment Agreement with the Company dated as of May 26, 2005. biz.yahoo.com